Cloud-based tools for Cerebral Palsy neuroimaging

Tools for interpreting findings from magnetic resonance images (MRI) can support clinical decision making for patients with cerebral palsy (CP).

Neuroimaging showing a scan of an infant brain scanned at 30 weeks and at 40 weeks, showing the rapid development that happens during those weeks. The scans are on a black background with different colours representing different areas of the brain

The rapid cortical development of an infant between 30 weeks gestation age (left) and 40 weeks (right).

The challenge

CP is the most common motor disability in childhood, associated with cognitive, behavioural and motor deficits.

Early and accurate identification of CP and implementation of targeted early interventions can be facilitated by MRI. However, current imaging tools are limited by the inability to account for severe image artefacts or pathology.

As such, clinicians use MRIs only in a qualitative fashion. Quantitative measures, which could provide predictive biomarkers, are not currently used.

Our response

We are developing a suite of algorithms that quantify brain structure and microstructure from MRIs. The software tools are robust to severe brain injury and motion artefacts.

Our approach enables the quantitative characterisation of brain structure (e.g. cortical morphology). This allows for increased understanding of biomarkers of brain structure and can contribute to the prediction of patient outcomes. Overall, our algorithms facilitate accurate prognosis from MRI.


Our tools have been used to characterise the microstructural properties of the neonatal brain. They have also been used to identify biomarkers to predict developmental delay and neurodevelopmental outcome.

We’ve delivered these tools via MILXcloud for research and clinical collaborators to access.

We’re currently investigating the utility and implementation of the tools for clinical reporting. This includes outlining the biomarkers derived from prediction models and providing estimates of patient outcomes to support decision making around patient-tailored treatments.